Antisoma's ASI411 shrinks tumor 70% in renal cancer patient

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Antisoma plc said a second late-stage renal cancer patient in its phase 1 trial of AS1411 has experienced tumor shrinkage of 70% six months after starting treatment with ASI411.

The patient had four separate tumors at different sites, and had relapsed after three prior therapies of interleukin-2, gemcitabine and interferon plus Avastin.

The trial includes 12 patients with renal cancer and five with lung cancer.

The biopharmaceutical company, based in London and Louisville, Ky., said preclinical studies show ASI411 activity in other solid and blood cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.